SIX Swiss Exchange · Healthcare
Invest in Kuros Biosciences stock from India
Indian and foreign residents can buy Kuros Biosciences (KURN) shares directly through Paasa.
By Paasa · Updated
Kuros Biosciences at a glance
- Price
- CHF 17.61+CHF 0.43 (2.50%)
- Market cap
- CHF 694.53M
- Day range
- CHF 17.01 – CHF 17.81
- P/E
- 97.29
- Dividend yield
- None
- Volume
- 159.19K
- 1 month
- -18.77%
- 6 months
- -19.44%
- YTD
- -34.00%
- 1 year
- -27.11%
- 5 years
- +610.08%
Kuros Biosciences statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 121.3M | CHF 75.6M | CHF 33.6M | CHF 18.0M | CHF 13.8M |
| Gross profit | CHF 104.8M | CHF 62.0M | CHF 23.9M | CHF 10.8M | CHF 10.1M |
| Operating income | CHF 7.3M | −CHF 5.0M | −CHF 13.2M | −CHF 13.4M | −CHF 8.8M |
| Net income | CHF 2.1M | −CHF 3.7M | −CHF 13.7M | −CHF 14.6M | −CHF 7.5M |
| Earnings per share | CHF 0.06 | −CHF 0.10 | −CHF 0.38 | −CHF 0.43 | −CHF 0.23 |
| EBITDA | CHF 10.1M | −CHF 561.0K | −CHF 6.8M | −CHF 8.8M | −CHF 5.3M |
| Total assets | CHF 107.2M | CHF 84.5M | CHF 71.5M | CHF 82.9M | CHF 91.3M |
| Total debt | CHF 3.9M | CHF 1.8M | CHF 2.1M | CHF 1.9M | CHF 8.9M |
| Cash and short-term investments | CHF 15.7M | CHF 17.5M | CHF 14.2M | CHF 24.1M | CHF 28.6M |
| Shareholders' equity | CHF 66.9M | CHF 58.7M | CHF 56.7M | CHF 68.9M | CHF 77.0M |
| Operating cash flow | −CHF 377.9K | CHF 3.1M | −CHF 8.8M | −CHF 7.3M | −CHF 5.5M |
| Free cash flow | −CHF 2.4M | CHF 2.0M | −CHF 9.2M | −CHF 7.7M | −CHF 5.8M |
| Capital expenditure | −CHF 2.0M | −CHF 1.1M | −CHF 326.0K | −CHF 400.0K | −CHF 374.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| BB Biotech | BION.SW | CHF 51.10 | CHF 2.82B |
| SKAN | SKAN.SW | CHF 66.90 | CHF 1.50B |
| PolyPeptide | PPGN.SW | CHF 44.10 | CHF 1.46B |
| Aevis Victoria | AEVS.SW | CHF 15.95 | CHF 1.35B |
| Idorsia | IDIA.SW | CHF 4.44 | CHF 1.17B |
| Medartis | MED.SW | CHF 86.20 | CHF 1.07B |
| Cosmo Pharmaceuticals | COPN.SW | CHF 58.70 | CHF 1.01B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Kuros Biosciences from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search KURN and buy
Find Kuros Biosciences by name or by its ticker, KURN, and place your order.
Why invest in Kuros Biosciences from India
What Kuros Biosciences does
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. Kuros Biosciences operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Kuros Biosciences stock from India?
Yes. Indian residents and NRIs can buy Kuros Biosciences (KURN) shares directly through Paasa. Kuros Biosciences is listed on the SIX Swiss Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Kuros Biosciences shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.